...
首页> 外文期刊>Oncology letters >Regulator of G-protein signaling 5 enhances portal vein invasion in hepatocellular carcinoma
【24h】

Regulator of G-protein signaling 5 enhances portal vein invasion in hepatocellular carcinoma

机译:G蛋白信号传导调节剂5增强了肝细胞癌中的门静脉侵袭

获取原文
获取原文并翻译 | 示例

摘要

Portal vein invasion (PVI) is a major prognostic factor in hepatocellular carcinoma (HCC). The aim of the present study was to identify molecules that regulate PVI. Sections of cancerous tissue, paired noncancerous tissue and the PVI area were collected from 3 frozen HCC sections, using laser microdissection. The present study focused on 3 upregulated molecules, integrin beta 3 (ITGB3), secreted phosphoprotein 1 (SPP1) and regulator of G-protein signaling 5 (RGS5), and 2 molecules that were downregulated in PVI tissue compared with cancer tissue, metallothionein 1G (MT1G) and metallothionein 1H (MT1H), as determined by cDNA microarray analysis. Reverse transcription-quantitative polymerase chain reaction analysis of 32 HCC cases revealed that RGS5 mRNA levels were significantly increased and MT1 G and MT1H mRNA levels were significantly decreased in cancerous tissue compared with noncancerous tissue. However, there was no significant difference in ITGB3 and SPP1 expression. There were no significant differences between the expression of these molecules and any clinicopathologic factors, including PVI. Immunohistochemical staining for RGS5 in 60 HCC cases demonstrated that RGS5 protein levels were higher in cancerous tissue compared with paired noncancerous tissue in 63.3% of HCC cases. Furthermore, high expression of RGS5 in cancerous tissue was significantly associated with PVI and tended to be associated with intrahepatic metastasis. Confluent multinodular type was significantly more frequent in cases with high expression of RGS5 in the cancerous tissue. Therefore, RGS5 may be a useful prognostic biomarker as well as a potential target of molecular therapy to treat HCC.
机译:门静脉侵袭(PVI)是肝细胞癌(HCC)中的主要预后因素。本研究的目的是鉴定调节PVI的分子。使用激光微粉切割从3个冷冻的HCC部分收集癌组织,成对的非癌症组织和PVI区域的部分。本研究重点关注3个上调分子,整联蛋白β3(ITGB3),分泌的磷蛋白1(SPP1)和G-蛋白信号传导5(RGS5)的调节剂,以及与癌组织的PVI组织中下调的2个分子,Metallothion 1g (MT1G)和金属硫蛋白1H(MT1H),通过cDNA微阵列分析测定。逆转录定量聚合酶链反应分析32个HCC病例显示,与非癌组织相比,癌组织中,RGS5 mRNA水平显着增加,MT1g和MT1H mRNA水平显着降低。但是,ITGB3和SPP1表达没有显着差异。这些分子表达与任何临床病理因子之间没有显着差异,包括PVI。 60 HCC病例中RGS5的免疫组织化学染色证明癌组织中的RGS5蛋白水平较高,而63.3%的HCC病例中的成对非癌组织相比。此外,癌组织中RGS5的高表达与PVI显着相关,并倾向于与肝内转移相关。在癌组织中具有高表达的情况下,汇合多个涂层型显着更频繁。因此,RGS5可以是有用的预后生物标志物以及治疗HCC的分子治疗的潜在靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号